Analyst Price Target is GBX 315
▼ -5.49% Downside Potential
This price target is based on 8 analysts offering 12 month price targets for Haleon in the last 3 months. The average price target is GBX 315, with a high forecast of GBX 376 and a low forecast of GBX 250. The average price target represents a -5.49% upside from the last price of GBX 333.30.
Current Consensus is
The current consensus among 8 contributing investment analysts is to hold stock in Haleon. This rating has held steady since August 2022, when it changed from a Buy consensus rating.
Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements. Its portfolio of brands include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was incorporated in 2021 and is headquartered in Brentford, the United Kingdom.